The ALK/MET inhibitor crizotinib is a promising cancer therapy used primarily for the treatment of non-small cell lung cancer [37], and demonstrated cytotoxic effects on cervical cancer [38], ovarian cancer [39], and also chordoma cell [12, 13]. This evidence concerns the gene MET and cancer.